Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Januari 2019. De goedkeuring komt eraan in H1-2019 !!!
Volgen
Piet Particulier schreef op 2 januari 2019 11:32 :
Veel kopers ineens, dit gaat interessant worden.
8 einde van de dag?!
Ik ga eigenlijk uit van een wat hogere koers. Binnen een paar weken zou er zo maar een PB kunnen zijn dat de vragen zijn beantwoord.
Er beweegt iets... Opmerkelijk. Inside information?
Zou zo maar eens richting de 8,5 kunnen gaan vandaag. Men wil de boot niet missen op weg naar de goedkeuring!
Ook in duitsland wordt aan de weg getimmerd: careers.kiadis.com/vacancies/120451-k...
en eveneens een nieuwe vacature voor Marketing: careers.kiadis.com/vacancies/120448-h... voorbereidingen voor lancering in volle gang!
Zouden ze dit doen als ze niet 100% overtuigd zijn van goedkeuring? Dit is voor mij duidelijk. Atir gaat er komen...... As a Key Account Manager Germany at Kiadis Pharma, you will be responsible for; Leading the launch preparation then launching ATIR101 in Germany,
Net voor vorig weekend geposte vacature: "Leading the launch preparation then launching ATIR101 in Germany" ^ Kiadis Pharma is a biopharmaceutical company based in Amsterdam, The Netherlands. We focus on the treatment of blood cancers and inherited blood disorders aiming to make bone marrow transplantations, a risky procedure that is often the last hope for patients, safer and more efficient. This means we have a passionate team that is dedicated to make a huge difference for patients. If you are up to the challenge and would like to be part of our team, we are currently looking for a driven Key Account Manager Germany. As a Key Account Manager Germany at Kiadis Pharma, you will be responsible for; Leading the launch preparation then launching ATIR101 in Germany, alongside MSL colleague(s) from a commercial / customer facing perspective across key transplantation centres/ customers. Delivering against commercial targets that are set and acting as the voice of the German customer back into the above country commercial team. Areas of full responsibility; Being the primary commercial customer facing representative of Kiadis in Germany/ across agreed key accounts. Leading the local account planning process – account identification, prioritisation, key customer mapping and building of cross functional account plans. Set-up and execution of the wider Germany commercial plan – congresses, webinars, other key customer meetings. Leading execution of the customer facing account / activity plans to drive usage/ sales of ATIR101 through the launch phase in Germany. Linking with the European commercial/ marketing teams to provide customer insight / seek support and to define the design/ set-up of the Kiadis service capability. Areas of Support; Builds/ agrees local Key Account Plans with the partner MSL(s). Feeds relevant customer feedback/ objections/ insight into the European commercial team and seeks European level customer facing support as needed. Seeks additional and relevant internal and external training/ learnings opportunities to continue to develop expertise/ knowledge of the disease and therapy area. Over-all activities; Identify the high priority/ high potential transplantation centres to focus on for launch. Identify/ map out the key customers across the key centres that should be targeted for launch through initial introductory meetings. Build hospital/ centre level key account plans across all key stakeholders to prepare for launch. Own the launch/ sales line of ATIR101 in-line with agreed brand strategy across key transplantation centres – acting as the primary point contact from Kiadis across the end to end patient/ customer journey – and by executing the agreed customer call/ account plans in-line with the defined KPIs. Help set-up then leverage the wider / central Kiadis service support capability to support customers in the end to end process from patient and donor identification to longer term patient management. Set-up/ execute the account/ Germany specific wider commercial plan – speaker meetings, local congresses, local webinars etc. The ideal candidate / Role Requirements; You have a University Degree level. You have a significant (8+ years) sales and senior key account management experience in specialty/ hospital customer facing roles, including a track record of working effectively with specialists/ in a secondary or tertiary care setting. You are excellent in commercial project management. You are self-sufficient and driven, but also a strong team player with the ability to work cross-functionally as part of a multi-disciplinary / matrix team – in particular with in field medical colleagues. You have relevant experience of leading teams and creating sales plans from the ground up. You have a background ideally in Oncology/ Haematology and-or cell (gene) therapy. We offer A challenging position in an innovative, fast growing biotechnology company. You will be working in a fast-paced dynamic environment which provides the opportunity to make your own mark within the organization and build our ambitious HR team. You will be rewarded a competitive remuneration package, the opportunity for personal development and are able to contribute to make a huge difference for patients worldwide. For further information, please contact us by e-mail at recruitment@kiadis.com . If you're interested in the position please apply directly through the application button.
Nog een 2e werd gepost net voor vorig weekend: "Defining and owning the ATIR101 brand strategy for launch across Europe." ^ Kiadis Pharma is a biopharmaceutical company based in Amsterdam, The Netherlands. We focus on the treatment of blood cancers and inherited blood disorders aiming to make bone marrow transplantations, a risky procedure that is often the last hope for patients, safer and more efficient. This means we have a passionate team that is dedicated to make a huge difference for patients. If you are up to the challenge and would like to be part of our team, we are currently looking for a driven Head of Marketing As our Head of Marketing you are leading the European marketing effort to/ through the launch of ATIR101 – from concept to execution; brand strategy, positioning, essence, look and feel/ creative concept, commercial story flow/ messaging and ultimately the cross-channel / digital marketing approach and materials for training and launch. As a Head of Marketing at Kiadis Pharma, you will be responsible for; Defining and owning the ATIR101 brand strategy for launch across Europe. Defining and owning the positioning, essence, look and feel/ creative concept, commercial story flow/ messaging. All core marketing deliverables / content needed for launch – across all channels – on-line and offline – including materials / infrastructure needed for patient engagement/ support. Set-up and ownership of the external / commercial engagement plan – congresses, webinars, KOLs as relevant. All commercial training materials / training of customer facing teams needed for launch. Pre and post launch KPIs and targets. Leading the work across key functions – including Account Managers/ Head of Account Managers to define and agree the brand strategy for launch. Lead the process to choose an external marketing / comms agency to partner with for launch then work with/ manage the agency. Defining the marketing channel strategy/ mix for/ post launch and then lead the development of all associated content/ materials. Defining the training approach for the commercial Key Account Managers – and lead the preparation of associated materials. Preparing the content to be used at external congresses for commercial activities/ booths. The ideal candidate / Role Requirements; You have a University Degree level or higher, ideally with marketing accreditation. You have significant (8+ years) in and above country experience of leading strategic and operational digital/ multi-channel marketing work in Europe and/ or globally and in particular experience in leading product launches (from conception to post launch). You are strong in project and vendor management Needless to say you are astrong team player and leader with an ability to work cross-functionally as part of a multi-disciplinary / matrix team and to lead direct teams/ reports. Ideally experience in Oncology/ Haematology, cell (gene) therapy, speciality medicines or other We offer A challenging position in an innovative, fast growing biotechnology company. You will be working in a fast-paced dynamic environment which provides the opportunity to make your own mark within the organization and build our ambitious HR team. You will be rewarded a competitive remuneration package, the opportunity for personal development and are able to contribute to make a huge difference for patients worldwide. For further information, please contact us by e-mail at recruitment@kiadis.com . If you're interested in the position please apply directly through the application button.
Daar gaan we!! Straks flink door de 8,-
Aan iedereen op het forum mijn beste wensen voor een vreugdevol en succesrijk 2019 ! Ik vermoed dat het weer een woelig jaar wordt maar maakt dit het nu net niet spannend... Kiadis sowieso één van mijn favorieten net als Oxurion voor beiden moeten we echter (veel) geduld hebben ...
Zeker weten, en ik verwacht de 9 ook snel te zien, en dan is het hek van de dam.
niet euforisch worden ivm deze personeelsadvertenties...
Cerazeen schreef op 2 januari 2019 12:09 :
niet euforisch worden ivm deze personeelsadvertenties...
Dat was ik al. Dit is alleen weer een bevestiging
Lijkt een goede ontwikkeling, weer eens een bewijs dat Kiadis niet mee beweegt op het sentiment van de dag. Toch stap ik nog niet in, wil eerst een koers zien van tenminste € 10,00 gezien de ervaringen van de afgelopen tijd
Hey 8 euro, welcome back !
Allen een voorspoedig 2019 gewenst .
Dit gaat mooi zo, die EUR 8,50-9,00 die ik einde week verwachtte moet makkelijk haalbaar zijn zo! Ruim een week geleden weer vol in Kiadis gegaan, vooralsnog mooie timing.
Windkracht schreef op 2 januari 2019 12:29 :
Dit gaat mooi zo, die EUR 8,50-9,00 die ik einde week verwachtte moet makkelijk haalbaar zijn zo! Ruim een week geleden weer vol in Kiadis gegaan, vooralsnog mooie timing.
Gefeliciteerd, dat maakt weer wat goed van de verliezen die je afgelopen tijd met het aandeel hebt geleden. Komt goed
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
887,44
+0,99%
EUR/USD
1,0762
+0,34%
FTSE 100
8.213,49
+0,51%
Germany40^
18.017,10
+0,67%
Gold spot
2.301,75
0,00%
NY-Nasdaq Composite
16.156,33
+1,99%
Stijgers
Dalers